Replies to post #64097 on Biotech Values

[Biowatch]

AGIX +45% AGI-1067 meets endpoint for diabetes

http://biz.yahoo.com/iw/080731/0420780.html

On July 31, 2008, AtheroGenics, Inc. issued a press release to report the company's top-line results for the ANDES Phase 3 clinical trial of AGI-1067 for the treatment of Type-2 diabetes demonstrating that both doses (75mg and 150mg) of AGI-1067 met the primary efficacy endpoint of the reduction in glycosylated hemoglobin (A1c) versus placebo at the end of the study's six month dosing regimen. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.

The following exhibit is furnished as part of this current report on Form 8-K.

Exhibit No. Description
99.1 - Press Release dated July 31, 2008